Australian company Oventus Medical unveiled its latest research today on the international stage at the World Sleep Congress in Prague, which runs today through October 11.
Oventus’ latest clinical trials support previous data that shows the effectiveness of Oventus Airway Technology for obstructive sleep apnea patients who suffer nasal resistance.
Oventus founder and clinical director Chris Hart, M.Phil, BSc, BDSc, accompanies Danny Eckert, PhD, principal research scientist at Neuroscience Research Australia (NeuRA) at today’s presentation.
In a release, Hart says key findings include that nasal resistance was found to increase when patients with sleep apnea were lying down and that this change was larger than in previous studies with people without sleep apnea.
“Our technology is shown to be equally effective in patients with and without nasal resistance and that’s the big difference,” he says.
This aligns with previous clinical resistance findings and Hart and Eckert say it is in opposition to peer-reviewed data that indicated that increased nasal resistance may be a reason for non-response to standard mandibular advancement devices.
Oventus devices incorporate Oventus Airway Technology that acts like a “second nose.” Co-developed with the CSIRO, O2Vent is approved for snorers and those with mild to moderate OSA. The devices are particularly appropriate in patients who breathe through their mouths.
Hart says the developments come at an exciting time as Oventus partners with Modern Dental Group in the United States and Australia to expand its network of dentists using O2Vent devices.